Citi analyst Joanne Wuensch raised the firm’s price target on Bausch + Lomb (BLCO) to C$16 from C$15 and keeps a Neutral rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb initiated with a Neutral at Goldman Sachs
- Bausch + Lomb to Announce Q3 2025 Results and Host Investor Day
- Bausch + Lomb’s enVista Envy IOL Achieves Key Milestones in Clinical Trial
- Bausch + Lomb publishes enVista Envy trial results
- Needham medtech & diagnostics analysts hold analyst/industry conference call